| |
July 18-19, 2023 | Jersey City, NJ This is the only communications event for peer learning and networking exclusively for the life science community. Save $500, Register Today!
|
|
Today's Big NewsApr 3, 2023 |
|
Tuesday, April 11, 2023 | 12pm ET / 9am PT In this webinar we will guide you along the scientific data journey where you can discover smart ways to get from raw data to insights and how to achieve an automated, interconnected lab with data liquidity across the organization. Register now.
|
|
| By Conor Hale The DNA sequencing giant now has six months to completely divest its holdings in the company. The $8 billion acquisition deal closed in August 2021 before receiving a final sign-off from regulators. Illumina has maintained that it has kept Grail’s operations at arms’ length. |
|
|
|
By Nick Paul Taylor BioNTech is putting its COVID-19 vaccine dollars to work to add a new modality to its pipeline. Sitting on $15 billion, the German biotech has doled out $170 million upfront for the rights to two antibody-drug conjugates (ADC) in development at China’s Duality Biologics. |
By Ben Adams If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist. |
By Kevin Dunleavy With a new CEO in Paul McKenzie, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited. McKenzie and CSL’s chief medical officer Bill Mezzanotte shared their outlook for the drugmaker in an interview last week. |
|
Monday, April 24, 2023 | Boston, Massachusetts (and online) Intra-Target Microdosing (ITM) is a First-in-Human drug development approach that administers a drug microdose into a small target, generating therapeutic-level exposures in it and microdose exposures elsewhere, thus enabling collection of biomarkers. Join Us!
|
|
By Conor Hale Already popular with the parents of newborns, the makers of the Snoo motorized bassinet hope it will become the favored choice among hospitals and, perhaps one day, insurance providers. |
By Annalee Armstrong Sumitomo Pharma is doing a little bit of spring cleaning to bring a handful of biopharma units under one consolidated company to be named Sumitomo Pharma America. |
By Angus Liu Just as Akebia Therapeutics challenges an FDA complete response letter for oral anemia drug vadadustat, the biotech has offered top-line data for a regimen with a reduced dosing frequency. |
By Max Bayer Opthamology-focused gene therapy biotech Vedere Bio II, the successor to a Novartis-bought biotech that was scooped up in 2020, is closing up shop after failing to impress in preclinical studies. |
By Conor Hale In its announcement, the Finnish developer Bioretec said its RemeOs inserts were the first bioresorbable metal implants to score a green light from the agency. |
By Fraiser Kansteiner A New York federal court tossed investors’ claims against Viatris “in their entirety,” granting the company’s bid for summary judgement in a nearly 7-year-old lawsuit. The securities fraud case, first lobbed at Mylan in 2016, asserted the company “misled investors by obscuring underlying violations of antitrust law and regulatory law." |
By Conor Hale The Prima system aims to partially restore the ability to see at the center of a person’s visual field, the area most affected by the type of age-related macular degeneration known as dry AMD. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
|
| Tuesday, April 11, 2023 | 1pm ET / 10am PT Achieving interoperability in healthcare can be a daunting task, but sharing and collaborating with data has the potential to generate better clinical outcomes, enable new care models, and enhance patient experience. Join healthcare industry experts for this important roundtable discussion to learn more. Register now. |
|
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
